Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria

References

• Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003;12:22–33
   Google Scholar
• World Health Organization. World Health Report 2001: Mental Health – New Understanding. New Hope. Geneva: WHO; 2001
   Google Scholar
• Bundesministerium Für Gesundheit und Frauen. Mental health in Austria. Selected annotated statistics from the Austrian mental health reports 2001 and 2003. Vienna, The Federal Ministry of Health and Women; 2003
   Google Scholar
• Hofmacher MM, Rack H. Health care systems in transition. Austria. http://www.euro.who.int/observatory/toppage 2001;1–94. [Accessed 8/1/03]
   Google Scholar
• Kessler R. The national comorbidity survey. Int Rev Psychiatry 1994;6:365–76
   Google Scholar
• Huffman JC, Perlis RH. The development of new antidepressants: focus on duloxetine and escitalopram. Harv Rev Psychiatry 2003;11:30–6
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 2003; 21:1185–209
   PubMed Web of Science ®Google Scholar
• François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002;5:91–107
   Google Scholar
• François C, Toumi M, Aakhus A-M, et al. A pharmacoeconomic evaluation of escitalopram, a new SSRI: a comparison of cost-effectiveness between escitalopram, a new SSRI, citalopram, fluoxetine and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003;4:12–9
   Google Scholar
• Kasper S, Lehofer M, Aschauer H, et al. Depression. Medikamentöse Therapie. Ärztemagazin Spezial 2002;15:2–12
   Google Scholar
• Kasper S, Möller HJ, Müller-Spahn F. Depression. Diagnose und Pharmakotherapie. 2. Überarbeitete Auflage. Stuttgart-New York: Thieme; 2004
   Google Scholar
• Lepola U, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18: 211–7
   Google Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8: 181–8
   Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10:29–35
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Leventhal RM. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001;4:113–8
   Google Scholar
• Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001;62:135–42
   PubMed Web of Science ®Google Scholar
• Brown MCJ, Nimmerrichter AA, Guest JF. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur Psychiatry 1999;14:230–44
   Google Scholar
• Statistik Austria. Statistisches Jahrbuch 2003. http:// www.statistik.at/jahrbuch/pdfe/k03.pdf [Accessed 8/7/03]
   Google Scholar
• Organization of social protection. Austria, 2003 http:// europa.eu.int/comm/employment_social/missoc/2002/org_en.p df [Accessed 8/2/03]
   Google Scholar
• Hauptverband der Österreichischen Sozialversicherungsträger. Handbuch der Österreichischen Sozialversicherung 2002. Wien: Österreichischen Sozialversicherung; 2002. p. 146
   Google Scholar
• Lundbeck. Resource utilization survey. Data on file. Paris: H Lundbeck A/S; 2001
   Google Scholar
• Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive worktime among US workers with depression. J Am Med Assoc 2003;289:3135–44
   PubMed Web of Science ®Google Scholar
• Kessler R, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood) 1999;18:163–71
   PubMed Web of Science ®Google Scholar
• Simon GE, Barber C, Birnbaum HG, et al. Depression and work productivity: the comparative costs of treatment versus nontreatment. J Occup Environ Med 2001;43:2–9
   PubMed Web of Science ®Google Scholar
• Straton JB, Cronholm P. Are paroxetine, fluoxetine, and sertraline equally effective for depression? J Fam Pract 2002;51:285
   PubMedGoogle Scholar
• Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. J Am Med Assoc 2001;286:2947–55
   PubMed Web of Science ®Google Scholar
• Schulenburg JMGvd, Greiner W, Schöffski O. Empfehlungen zur Gesundheitsökonomischen Evaluation - Hannoveraner Konsens. Zeitschrift für Algemeinmedizin 1996;72:485–90
   Google Scholar
• Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171–89
   PubMed Web of Science ®Google Scholar
• Observational study of seropram: data on file. Paris: H Lundbeck A/S; 2001
   Google Scholar
• IMS Health. IMS DATAview. IMS data QTR/12/02; 2002
   Google Scholar
• Wiener Gebietskrankenkasse. Wien: Gebietskrankenkasse; 2003
   Google Scholar
• Bundesministerium für Gesundheit und Frauen (BMGF). Kostenstellenstatistik und -kostenrechnung 2001. Wien: Bundesministerium für Gesundheit und Frauen (BMGF); 2001
   Google Scholar
• Palmer CS, Revicki DA, Genduso LA. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 1998;4:345–55
   Google Scholar
• Runeson B, Wasserman D. Management of suicide attempters: what are the routines and the costs? Acta Psychiatr Scand 1994;90:222–8
   PubMed Web of Science ®Google Scholar